DRUG

Bright Minds Biosciences Inc

• Benzinga·03/30 09:57

  BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target

• TipRanks·03/30 09:55

  Buy Rating on BMB-101 Driven by Strong Phase 2 Epilepsy Data, Differentiated Safety, and Prader–Willi Upside Supporting DCF Valuation

• Benzinga·03/27 17:28

  'Bipartisan Senators File Bill To Support Psychedelics Research And Treatment For Veterans' - Marijuana Moment

• TipRanks·03/05 15:15

  Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results

• Benzinga·03/04 16:04

  HC Wainwright & Co. Maintains Buy on Bright Minds Biosciences, Raises Price Target to $145

• TipRanks·03/04 13:39

  Bright Minds price target raised to $145 from $115 at H.C. Wainwright

• Reuters·03/04 13:34

  BRIGHT MINDS BIOSCIENCES INC <DRUG.N>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $145 FROM $115

• Reuters·02/25 21:44

  Bright Minds Biosciences to Present at TD Cowen 46th Annual Health Care Conference

• TipRanks·02/17 11:56

  Compelling Phase 2 Data and Prader–Willi Upside Support Buy Rating and Favorable Risk/Reward for DRUG

• Benzinga·02/17 11:00

  BTIG Maintains Buy on Bright Minds Biosciences, Maintains $147 Price Target

• TipRanks·02/13 15:45

  De-Risked Neurology Pipeline and Pivotal 2026 Catalysts Underpin Buy Rating on BMB-101 Franchise

• TipRanks·02/13 14:21

  Bright Minds price target lowered to $126 from $142 at Baird

• TipRanks·02/13 12:44

  Bright Minds Biosciences Files Q1 FY2026 Financials Showing Strong Cash, Higher R&D Loss

• Reuters·02/13 11:07

  Bright Minds Biosciences Reports Q4 Net Loss of CAD 7.57 Million

• TipRanks·02/03 02:47

  BTIG Sticks to Its Buy Rating for Bright Minds Biosciences (DRUG)